Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Shannon Cook

Nurse Practitioner, Family Cheyenne, WY Nurse Practitioner

NPI 1952384927 CMS profile 10780940

800 E 20Th St, Cheyenne, WY 82001

Open in the dashboard

General payments

$372

16 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Shannon Cook of Cheyenne, WY is reported in the CMS Open Payments database as having received $372 across 16 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 52nd percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $202 7
2024 General $35 2
2023 General $39 2
2022 General $77 4
2021 General $19 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Shannon Cook
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Shannon Cook were reported at $202. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Shannon Cook Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $19 $124 $35–$379 $132
2022 $77 $141 $44–$430 $149
2023 $39 $154 $49–$476 $160
2024 $35 $165 $51–$504 $164
2025 $202 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Boston Scientific Corporation $77 1 payment
  2. Novo Nordisk Inc $55 3 payments
  3. GlaxoSmithKline, LLC. $38 2 payments
  4. AstraZeneca Pharmaceuticals LP $31 2 payments
  5. Lundbeck LLC $29 1 payment
  6. Novartis Pharmaceuticals Corporation $25 1 payment
  7. Puma Biotechnology, Inc. $24 1 payment
  8. Amgen Inc. $22 1 payment
  9. Pfizer Inc. $19 1 payment
  10. Phadia US Inc. $19 1 payment
  11. Other $32 2 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $356 15 payments
  2. Education $16 1 payment
Products named General payments · program years 2021–2025
  1. WATCHMAN $77 1 payment
  2. Ozempic $55 3 payments
  3. RYBELSUS $37 2 payments
  4. REXULTI $29 1 payment
  5. LEQVIO $25 1 payment
  6. NERLYNX $24 1 payment
  7. Otezla $22 1 payment
  8. REPATHA $22 1 payment
  9. SHINGRIX $21 1 payment
  10. PREMARIN $19 1 payment
  11. Other $103 6 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 131 drugs

Part D claims

7,896

Median for Nurse Practitioner: 389

Drug cost

$493,003

Median for Nurse Practitioner: $21,885

Branded share of claims

15.9%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 155 $122,562
Avonex (4 Pack) Interferon Beta-1a Brand 11 $87,263
Trulicity Dulaglutide Brand 45 $57,821
Xarelto Rivaroxaban Brand 42 $44,756
Farxiga Dapagliflozin Propanediol Brand 42 $22,575
Ozempic Semaglutide Brand 15 $19,303
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 15 $9,934
Jardiance Empagliflozin Brand 13 $8,834
Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog Brand 15 $7,942
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 26 $6,110

The 10 drugs with the highest cost, of 131 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 40 billing codes

Paid by Medicare

$132,413

Of which drugs: $41,639

Medicare patients

410

Average age 74

Services billed

5,216

308 women, 102 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 69%
Arthritis 40%
Depression 30%
Diabetes 26%
Ischemic heart disease 21%
Osteoporosis 17%
Atrial fibrillation 16%
Chronic kidney disease 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 16 1,200 $24,739
Sarscov2 vac 50 mcg/0.5ml im 91322 Office 38 42 $6,438
Vaccine for influenza for injection into muscle 90662 Office 69 69 $5,646
Vaccine for pneumococcal polysaccharide for injection beneath the skin or into muscle, patient 2 years or older 90732 Office 31 31 $2,646
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 49 344 $225
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 52 200 $157
Injection, methylprednisolone acetate, 1 mg J1010 Office 17 1,360 $127
Injection, ceftriaxone sodium, per 250 mg J0696 Office 14 98 $31
Injection, ketorolac tromethamine, per 15 mg J1885 Office 12 52 $28

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Otsuka America Pharmaceutical, Inc. $16
$16 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

16 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Wyoming

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record